参考资料
[1]pedro m folegatti, katie j ewer, parvinder k aley, et al., (2020). safety and immunogenicity of the chadox1 ncov-19 vaccine against sars-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. the lancet, https://doi.org/10.1016/s0140-6736(20)31604-4
[2]feng-cai zhu, xu-hua guan, yu-hua li, et al., (2020). immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. the lancet, https://doi.org/10.1016/s0140-6736(20)31605-6
[3]folegatti pm, bittaye m, flaxman a, et al. safety and immunogenicity of a candidate middle east respiratory syndrome coronavirus viralvectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. lancet infect dis 2020; 20: 816–26.
[4]ugur sahin, alexander muik, evelyna derhovanessian, et al., (2020). concurrent human antibody and th1 type t-cell responses elicited by a covid-19 rna vaccine. https://doi.org/10.1101/2020.07.17.20140533
